Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Rating of "Hold" from Analysts

Key Points

• Analyst consensus is “Hold” for Upstream Bio, with four buys, two holds and one sell among seven analysts. The average 12-month price target is $29.67, although recent targets ranged from $9 to $36.
• UPB shares opened at $5.34, near their 12-month low of $5.21 and well below the high of $33.68. The company has a market capitalization of approximately $292.5 million.
• Upstream Bio reported a quarterly loss of $0.73 per share, slightly better than expectations, and revenue of $0.77 million versus the $0.56 million consensus. Several institutional investors, including Norges Bank and BlackRock, recently established positions in the company.

Shares of Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) have been assigned an average rating of "Hold" from the seven analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $29.6667.

A number of equities research analysts recently weighed in on UPB shares. Wall Street Zen downgraded shares of Upstream Bio from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 15th. Truist Financial cut their target price on shares of Upstream Bio to $25.00 and set a "buy" rating on the stock in a report on Tuesday, August 11th. Weiss Ratings upgraded Upstream Bio from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, August 17th. HC Wainwright reaffirmed a "buy" rating and set a $36.00 target price on shares of Upstream Bio in a report on Wednesday, September 2nd. Finally, JPMorgan Chase & Co. increased their price target on Upstream Bio from $8.00 to $9.00 and gave the stock a "neutral" rating in a research report on Friday, August 14th.

Upstream Bio Price Performance

Upstream Bio stock opened at $5.34 on Friday. Upstream Bio has a 12 month low of $5.21 and a 12 month high of $33.68. The company has a fifty day moving average price of $6.58 and a two-hundred day moving average price of $7.73. The company has a market cap of $292.47 million, a PE ratio of -1.84 and a beta of 1.28.

Upstream Bio (NASDAQ:UPB - Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.73) earnings per share for the quarter, topping analysts' consensus estimates of ($0.74) by $0.01. Upstream Bio had a negative net margin of 4,955.67% and a negative return on equity of 48.40%. The company had revenue of $0.77 million for the quarter, compared to analysts' expectations of $0.56 million. Equities research analysts anticipate that Upstream Bio will post -2.84 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Norges Bank bought a new stake in Upstream Bio in the fourth quarter valued at $78,264,000. BlackRock Inc. bought a new position in shares of Upstream Bio during the second quarter worth about $25,973,000. Y Intercept Hong Kong Ltd grew its position in shares of Upstream Bio by 2,049.2% during the first quarter. Y Intercept Hong Kong Ltd now owns 1,000,631 shares of the company's stock worth $9,006,000 after acquiring an additional 954,072 shares during the last quarter. SEB Asset Management AB acquired a new stake in shares of Upstream Bio in the 1st quarter worth about $7,906,000. Finally, Parkman Healthcare Partners LLC acquired a new stake in shares of Upstream Bio in the 2nd quarter worth about $6,472,000.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and immune-mediated diseases. The company's research is centered on targeting biological pathways involved in chronic inflammation, with the goal of addressing conditions that may not be adequately controlled by existing therapies.

Upstream Bio's lead product candidate is verekitug, a monoclonal antibody designed to block thymic stromal lymphopoietin (TSLP), an epithelial-cell-derived cytokine that plays a role in initiating and sustaining allergic and inflammatory responses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.